

해외 바이오의약품 임상 현황 ('22년 10월 3주)

한국바이오의약품협회, 2022.10.25.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2022.10.17. ~ 2022.10.23.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05242965	A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer	Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Biological: Sargramostim	University of Washington United States Department of Defense	Phase 2	https://clinicaltrials.gov/show/NCT05242965
NCT05569148	A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe	Combination Product: Faricimab PFS Configuration	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/show/NCT05569148
NCT05463848	Surgical Pembro +/- Olaparib w TMZ for rGBM	Drug: Pembrolizumab Drug: Olaparib Drug: Temozolomide	Patrick Y. Wen, MD Merck Sharp & Dohme LLC Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/show/NCT05463848
NCT05259839	A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma	Drug: ABBV-383 Drug: Dexamethasone Drug: Lenalidomide Drug: Pomalidomide Drug: Nirogacestat Drug: Daratumumab	TeneoOne Inc.	Phase 1	https://clinicaltrials.gov/show/NCT05259839
NCT04991025	Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery	Drug: Cisplatin Drug: Pemetrexed Drug: Gemcitabine Drug: Carboplatin Drug: Certolizumab Drug: Nivolumab	Memorial Sloan Kettering Cancer Center	Phase 2	https://clinicaltrials.gov/show/NCT04991025
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Drug: Alectinib Drug: Entrectinib Drug: Pralsetinib Drug: Durvalumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/show/NCT05170204
NCT05498155	Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer	Drug: Neoadjuvant Olaparib monotherapy group Combination Product: Neoadjuvant combination therapy with olaparib plus durvalumab	AstraZeneca	Phase 2	https://clinicaltrials.gov/show/NCT05498155
NCT05584631	IVIG vs SCIG in CIDP	Drug: Intravenous immune globulin G Drug: Subcutaneous immune globulin G	Rutgers, The State University of New Jersey	Phase 1	https://clinicaltrials.gov/show/NCT05584631
NCT05556226	Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants	Drug: ABBV-154 Dose Formulation A Drug: ABBV-154 Dose Formulation B	AbbVie	Phase 1	https://clinicaltrials.gov/show/NCT05556226

○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05409612	Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients	Biological: Supemtek® Biological: Vaxigriptetra®	Assistance Publique - H ^ô pitaux de Paris Sanofi Pasteur, a Sanofi Company Hospices Civils de Lyon	Phase 3	https://clinicaltrials.gov/show/NCT05409612

○ 독일 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05259839	A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma	Drug: ABBV-383 Drug: Dexamethasone Drug: Lenalidomide Drug: Pomalidomide Drug: Nirogacestat Drug: Daratumumab	TeneoOne Inc.	Phase 1	https://clinicaltrials.gov/show/NCT05259839

○ 중국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05562947	A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration	Device: PDS with ranibizumab (100 mg/mL) Drug: Ranibizumab (10 mg/mL)	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/show/NCT05562947
NCT05562024	TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/Refractory Neuroblastoma	Biological: T cell injection targeting FLT3 chimeric antigen receptor	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Phase 1	https://clinicaltrials.gov/show/NCT05562024

해외 바이오의약품 임상 현황 ('22년 10월 3주)

한국바이오의약품협회, 2022.10.25.

NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Drug: Alectinib Drug: Entrectinib Drug: Pralsetinib Drug: Durvalumab	Hoffmann-La Roche	Phase 3	https://ClinicalTrials.gov/show/NCT05170204
-----------------------------	---	--	-------------------	---------	---

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05259839	A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma	Drug: ABBV-383 Drug: Dexamethasone Drug: Lenalidomide Drug: Pomalidomide Drug: Nirogacestat Drug: Daratumumab	TeneoOne Inc.	Phase 1	https://ClinicalTrials.gov/show/NCT05259839
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Drug: Alectinib Drug: Entrectinib Drug: Pralsetinib Drug: Durvalumab	Hoffmann-La Roche	Phase 3	https://ClinicalTrials.gov/show/NCT05170204